GGM Financials’s Opus Genetics IRD Stock Holding History

GGM Financials’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,005	Closed	-$4.13K	–	299
2026 Q2	$4.13K	Buy	+1,005	New	+$4.69K	﹤0.01%	249

Other funds holding IRD

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

SPAL

StoneRidge PMG Advisors, LLC Radnor, Pennsylvania $142M AUM

StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return

GGM Financials's IRD Position: Q3 2026 in Review

GGM Financials sold out of Opus Genetics (IRD) in Q3 2026, closing a stake of 1,005 shares — an estimated $4.13K sold.

GGM Financials first reported a position in IRD in Q2 2026 and held it in 1 quarter. The position peaked at $4.13K in Q2 2026. 26 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

GGM Financials reported no remaining Opus Genetics position as of Q3 2026 after selling out during the quarter.
GGM Financials sold 1,005 Opus Genetics shares in Q3 2026, an estimated $4.13K.
GGM Financials first reported a position in Opus Genetics in Q2 2026 and held it in 1 quarter.
GGM Financials's Opus Genetics position peaked at $4.13K in Q2 2026.
26 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on GGM Financials's 13F filing for Q3 2026, filed 5 Nov 2026.